The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response.

about

Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG The immune microenvironment of human tumors: general significance and clinical impact Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape?

P2860

Q36625824-A27721AE-7993-47FC-93E6-F4CA285C6A07 Q37028764-CC65386A-9CBE-4A29-81E4-3E6A9D0ADEBE Q38239661-F13D98CD-E7B6-4A45-A2FE-58FA596129B6

P2860

The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response.

Item

http://www.wikidata.org/entity/Q42143991

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

The ultimate goal of curative ...... ve anti-tumor immune response.

@en

The ultimate goal of curative ...... ve anti-tumor immune response.

@nl

type

Item

label

The ultimate goal of curative ...... ve anti-tumor immune response.

@en

The ultimate goal of curative ...... ve anti-tumor immune response.

@nl

prefLabel

The ultimate goal of curative ...... ve anti-tumor immune response.

@en

The ultimate goal of curative ...... ve anti-tumor immune response.

@nl

P1476

The ultimate goal of curative ...... ve anti-tumor immune response.

@en

P2093

Catherine Sautès-Fridman

http://www.w3.org/2001/XMLSchema#string

Franck Pagès

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Teillaud

http://www.w3.org/2001/XMLSchema#string

P2860

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review.

Immunosurveillance in human non-viral cancers.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2011.00066

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Guido Kroemer

Laurence Zitvogel

Jérôme Galon

Catherine Sautès-Fridman

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224919243

http://www.w3.org/2001/XMLSchema#string

P698

22566855

http://www.w3.org/2001/XMLSchema#string

P932

3341952

http://www.w3.org/2001/XMLSchema#string

The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response.

about

P2860

P2860

The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P932